Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pradaxa Shines On Strength Of Results, But Panelists Wary Of Future Trials With Similar Design

This article was originally published in The Pink Sheet Daily

Executive Summary

Boehinger Ingelheim's dabigatran eked out a unanimous endorsement from FDA's Cardio-Renal Advisory Committee, but the panel had concerns about the potential for bias from the open-label trial design.
Advertisement

Related Content

FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option
FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option
FDA's Pradaxa Quandary: Clearing Both Doses Could Mask Dabigatran's Superiority
FDA's Pradaxa Quandary: Clearing Both Doses Could Mask Dabigatran's Superiority
FDA Supports Pradaxa Approval, But Without Superiority Claim
FDA Supports Pradaxa Approval, But Without Superiority Claim

Topics

Advertisement
UsernamePublicRestriction

Register

PS071204

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel